Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases

被引:5
作者
Dara, Praneet [1 ,2 ]
Farooqui, Zeba [2 ]
Mwale, Fackson [3 ]
Choe, Chungyoul [4 ]
van Wijnen, Andre J. [2 ,5 ]
Im, Hee-Jeong [2 ,6 ]
机构
[1] Des Moines Univ DMU, Osteopath Med Sch, Des Moines, IA 50312 USA
[2] Univ Illinois Chicago UIC, Dept Biomed Engn, Chicago, IL 60607 USA
[3] SMBD Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd,Room F-602, Montreal, PQ H3T 1E2, Canada
[4] Sungkyunkwan Univ SKKU, Med Res Inst, Sch Med, Suwon 16419, South Korea
[5] Univ Vermont UVM, Dept Biochem, Burlington, VT 05405 USA
[6] Jesse Brown Vet Affairs Med Ctr Chicago JBVAMC, Chicago, IL 60612 USA
基金
美国国家卫生研究院; 新加坡国家研究基金会;
关键词
pain; arthritis; osteoarthritis; cartilage; naltrexone; opiate; regenerative medicine; MULTIPLE-SCLEROSIS; FIBROMYALGIA; DEPRESSION; MANAGEMENT; ANXIETY; SAFETY; DELTA; TRIAL;
D O I
10.3390/biomedicines11061620
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic pain conditions create major financial and emotional burdens that can be devastating for individuals and society. One primary source of pain is arthritis, a common inflammatory disease of the joints that causes persistent pain in affected people. The main objective of pharmacological treatments for either rheumatoid arthritis (RA) or osteoarthritis (OA) is to reduce pain. Non-steroidal anti-inflammatory drugs, opioids, and opioid antagonists have each been considered in the management of chronic pain in arthritis patients. Naltrexone is an oral-activated opioid antagonist with biphasic dose-dependent pharmacodynamic effects. The molecule acts as a competitive inhibitor of opioid receptors at high doses. However, naltrexone at low doses has been shown to have hormetic effects and provides relief for chronic pain conditions such as fibromyalgia, multiple sclerosis (MS), and inflammatory bowel disorders. Current knowledge of naltrexone suggests that low-dose treatments may be effective in the treatment of pain perception in chronic inflammatory conditions observed in patients with either RA or OA. In this review, we evaluated the therapeutic benefits of low-dose naltrexone (LDN) on arthritis-related pain conditions.
引用
收藏
页数:12
相关论文
共 58 条
[1]   Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety [J].
Afshari, Reza ;
Khadem-Rezaiyan, Majid ;
Moghadam, Hoda Khatibi ;
Talebi, Mahdi .
TOXICOLOGICAL RESEARCH, 2020, 36 (01) :21-27
[2]  
[Anonymous], What Is MS?
[3]  
[Anonymous], 2021, PRACTITIONER, V1852, P9
[4]  
[Anonymous], 2011, Relieving pain in America: A blueprint for transforming prevention, care, education, and research, DOI DOI 10.3109/15360288.2012.678473
[5]  
Bennett Cathleen D, 2017, MD Advis, V10, P5
[6]   Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships [J].
Bruun-Plesner, Karin ;
Blichfeldt-Eckhardt, Morten Rune ;
Vaegter, Henrik Bjarke ;
Lauridsen, Joergen T. ;
Amris, Kirstine ;
Toft, Palle .
PAIN MEDICINE, 2020, 21 (10) :2253-2261
[7]   Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligends for Intracellular Toll-Like Receptors [J].
Cant, Rachel ;
Dalgleish, Angus G. ;
Allen, Rachel L. .
FRONTIERS IN IMMUNOLOGY, 2017, 8
[8]   DIFFERENTIAL-EFFECTS OF SPECIFIC DELTA AND KAPPA-OPIOID RECEPTOR ANTAGONISTS ON THE BIDIRECTIONAL DOSE-DEPENDENT EFFECT OF SYSTEMIC NALOXONE IN ARTHRITIC RATS, AN EXPERIMENTAL-MODEL OF PERSISTENT PAIN [J].
CATTANEO, I ;
KAYSER, V ;
GUILBAUD, G .
BRAIN RESEARCH, 1993, 623 (02) :201-207
[9]  
Codino Heidi, 2021, Integr Med (Encinitas), V20, P30
[10]  
Cohen SP, 2021, LANCET, V397, P2082, DOI 10.1016/S0140-6736(21)00393-7